132 related articles for article (PubMed ID: 2828898)
1. Antibody reactivity with Skinner HSV vaccine.
Muniu EM; Durham J; Shariff D; Hartley CE; Fuller A; Melling J; Wiblin C; Wilkins G; Buchan A; Skinner GR
Med Microbiol Immunol; 1987; 176(6):315-27. PubMed ID: 2828898
[TBL] [Abstract][Full Text] [Related]
2. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs.
Welch MJ; Ridgeway PH; Phillpotts RJ
FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207
[TBL] [Abstract][Full Text] [Related]
3. Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.
Skinner GR; Woodman CB; Hartley CE; Buchan A; Fuller A; Durham J; Synnott M; Clay JC; Melling J; Wiblin C; Wilkins J
Br J Vener Dis; 1982 Dec; 58(6):381-6. PubMed ID: 6293640
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model.
Chen MH; Zhou Z; Hartley CE; Cowan M; Skinner GR
Vaccine; 1986 Dec; 4(4):249-52. PubMed ID: 3026107
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of a herpes simplex subunit vaccine.
Cappel R; Sprecher S; De Cuyper F; De Braekeleer J
J Med Virol; 1985 Jun; 16(2):137-45. PubMed ID: 2989419
[TBL] [Abstract][Full Text] [Related]
6. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.
Skinner GR; Fink CG; Cowan M; Buchan A; Fuller A; Hartley CE; Durham J; Wiblin C; Melling J
Med Microbiol Immunol; 1987; 176(3):161-8. PubMed ID: 3037289
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection.
Erturk M; Phillpotts RJ; Welch MJ; Jennings R
Vaccine; 1991 Oct; 9(10):728-34. PubMed ID: 1661978
[TBL] [Abstract][Full Text] [Related]
8. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
[TBL] [Abstract][Full Text] [Related]
9. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
Berman PW; Gregory T; Crase D; Lasky LA
Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
[TBL] [Abstract][Full Text] [Related]
10. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
[TBL] [Abstract][Full Text] [Related]
13. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
[TBL] [Abstract][Full Text] [Related]
14. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
15. Determination of herpes simplex virus type-specific antibodies by solid-phase RIA on Helix pomatia lectin-purified antigens.
Suchánková A; Hirsch I; Krĕmár M; Vonka V
J Infect Dis; 1984 Jun; 149(6):964-72. PubMed ID: 6330240
[TBL] [Abstract][Full Text] [Related]
16. The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.
Skinner GR; Buchan A; Hartley CE; Turner SP; Williams DR
Med Microbiol Immunol; 1980; 169(1):39-51. PubMed ID: 6258035
[TBL] [Abstract][Full Text] [Related]
17. Role of bovine mammillitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects.
Skinner GR; Buchan A; Durham J; Cowan M; Davies J; Brookes K; Castrucci G
Vaccine; 1987 Mar; 5(1):55-9. PubMed ID: 3033927
[TBL] [Abstract][Full Text] [Related]
18. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis.
Skinner GR; Woodman C; Hartley C; Buchan A; Fuller A; Wiblin C; Wilkins G; Melling J
Dev Biol Stand; 1982; 52():333-44. PubMed ID: 6299842
[TBL] [Abstract][Full Text] [Related]
19. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
